Cytori Therapeutics
Cytori Begins Breast Reconstruction Study in Europe
Published in Cancer Weekly, May 13th, 2008
Cytori (NASDAQ:CYTX) received approval to begin its European stem and regenerative cell-enhanced breast reconstruction study in breast cancer patients who have undergone partial mastectomy. This is a post-market study designated as RESTORE II. Currently, there is no generally accepted reconstructive technique for partial mastectomy patients despite the fact that breast conserving therapy is standard practice in the treatment of women with breast cancer worldwide.
In this study, tissue loss resulting from partial mastectomy will be reconstructed with the patients' own fat tissue (adipose), which will be enhanced with their adipose-derived stem and regenerative cells....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-05-13)
More Articles from Cancer Weekly
- Breast Cancer
Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema - Cancer Gene Therapy
Researchers from Fourth Military Medical University provide details of new studies and findings in the area of cancer gene therapy - Cancer Vaccines
Research from Shanghai Jiao Tong University has provided new data on cancer vaccines - Cancer Vaccines
Research on cancer vaccines described by D. Atanackovic and colleagues - Cancer Vaccines
Research reports on cancer vaccines from E.N. Vinageras and colleagues provide new insights - Glioma
Research from CSL Limited broadens understanding of glioma - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
